Your browser is out of date
With an updated browser, you will have a better Medtronic website experience. Update my browser now.
Real- World Outcomes With SmartGuard™ Auto Mode Technology
Learn moreAutomatically adjusts insulin delivery every 5 minutes
To help your patients prevent highs and lows*
Increased Time in SmartGuard Auto Mode†
Compared to MiniMed™ 670G1 system
Improved MiniMed™ 770G Customer Experience
Compared to MiniMed™ 670G2 system
Patients can automatically upload their insulin and CGM data directly from their smartphone for easier patient care
Patients get notified on their phone
If they’re going high or low
CareLink™ Connect App
Data can be shared with up to 5 Care Partners
Always by your side
Largest global support team in the industry with 24/7 service
My Insights
Providing insights & encouragement based on CareLink™ observations
Medtronic data on file: MiniMed ™ 770G and MiniMed™ 670G data uploaded voluntarily by 59,333 users in the US to CareLink™ Personal, from Nov 2020 to 8 Aug 2022
Medtronic data on file: NPS satisfaction scores FY22Q4 MiniMed™ 770G vs 670G users, 30th July 2022
Any customer using the MiniMedTM 770G system will get access to our next technology, when available, at no cost.‡
Our next innovation goal is to reduce fingersticks and bring you an advanced algorithm with auto-correction bolus for easier mealtimes. Get access to the future by filling out the form below and learning more about the MiniMedTM 770G system.
Learn more about our future innovations.
87.5%
Time in
SmartGuardTM
Auto Mode1
156.2
mg/dL
Mean sensor
glucose1
7.0%
Mean Glucose
Management Indicator
(GMI)1
Medtronic data on file: MiniMed ™ 770G and MiniMed™ 670G data uploaded voluntarily by 59,333 users in the US to CareLink™ Personal, from Nov 2020 to 8 Aug 2022
Due to inherent analysis limitations, caution is advised when attempting to extrapolate these results to new patients. There could be significant differences.
Patients included in analysis must meet the following criteria: At least 10 days of sensor data after the SmartGuard™ initiation periods
Medtronic data on file: MiniMed™ 770G and MiniMed™ 670G data uploaded voluntarily by 11,231 users in the US to CareLink™ Personal with >10days of pre and post data from Nov 2020 to 8 Aug 2022. Due to inherent analysis limitations, caution is advised when attempting to extrapolate these results to new patients. There could be significant differences.
TheMiniMed™ 770G system with Bluetooth® connectivity enables automatic CareLink™ uploads, helping support meaningful conversations with your patients, whether in-person or via telehealth.
Your patients can now use their smartphones to view their data. This means they can easily and discreetly track their glucose levels and get notified of highs and lows.
Available for care partners, this app helps keep everyone in the loop. Up to five care partners can now follow a pump user and receive high and low notifications.
Refers to SmartGuard™ Auto Mode. Some user interaction required. Induvial results may vary.
Based on real world evidence comparing 54,009 MiniMed™ 670G users vs. 59,333 MiniMed™ 770G users. Due to inherent analysis limitations, caution is advised when attempting to extrapolate these results to new patients. There could be significant differences.
Software Upgrade Terms and Conditions
Important Safety Information: MiniMedTM 770G System with SmartGuardTM Technology
The MiniMed™ 770G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons two years of age and older requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed™ 770G system includes SmartGuard™ technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitoring (CGM) sensor glucose (SG) values and can suspend delivery of insulin when the SG value falls below or is predicted to fall below predefined threshold values.
The Medtronic MiniMed™ 770G system consists of the following devices: MiniMed™ 770G insulin pump, the Guardian™ Link (3) transmitter, the Guardian™ Sensor (3), one-press serter, the Accu-Chek® Guide Link blood glucose meter, and the Accu-Chek® Guide test strips. The system requires a prescription.
The Guardian™ Sensor (3) has not been evaluated and is not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. All therapy adjustments should be based on measurements obtained using a blood glucose meter and not on values provided by the Guardian™ Sensor (3).
All therapy adjustments should be based on measurements obtained using the Accu-Chek® Guide Link blood glucose meter and not on values provided by the Guardian™ Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the Accu-Chek® Guide Link blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site. It is not recommended to calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise.
WARNING: Do not use the SmartGuard™ Auto Mode for people who require less than 8 units or more than 250 units of total daily insulin per day. A total daily dose of at least 8 units, but no more than 250 units, is required to operate in SmartGuard™ Auto Mode.
WARNING: Do not use the MiniMed™ 770G system until appropriate training has been received from a healthcare professional. Training is essential to ensure the safe use of the MiniMed™ 770G system.
Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed™ 770G system has not been studied in pregnant women. For complete details of the system, including product and important safety information such as indications, contraindications, warnings and precautions associated with system and its components, please consult http://www.medtronicdiabetes.com/important-safety-information#minimed-770g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library
The Bluetooth® word mark and logos are registered trademarks owned by Bluetooth SIG, Inc. and any use of such marks by Medtronic is under license.”